Gregory M. Torre
Keine laufenden Positionen mehr
Karriereverlauf von Gregory M. Torre
Ehemalige bekannte Positionen von Gregory M. Torre
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SELLAS LIFE SCIENCES GROUP, INC. | Direktor/Vorstandsmitglied | 29.12.2017 | 27.04.2018 |
| Technik-/Wissenschafts-/F&E-Leiter | 29.12.2017 | 27.04.2018 | |
| General Counsel | 29.12.2017 | 27.04.2018 | |
| NPS PHARMACEUTICALS, INC. | General Counsel | 01.02.2006 | 31.07.2007 |
Elusys Therapeutics, Inc.
 Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | General Counsel | 22.12.2010 | - |
| Corporate Officer/Principal | - | - |
Ausbildung von Gregory M. Torre
| St. John's University | Doctorate Degree |
| Brooklyn Law School | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| General Counsel | 3 |
| Doctorate Degree | 1 |
| Graduate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SELLAS LIFE SCIENCES GROUP, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
NPS Pharmaceuticals, Inc.
 NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NPS Pharmaceuticals, Inc. developed drugs for bone and mineral disorders. It also developed Natpara for the treatment of adult hypoparathyroidism. The company was founded by Hunter Jackson and Thomas N. Parks on October 22, 1986 and is headquartered in Bedminster, NJ. | Health Technology |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | Health Technology |
- Börse
- Insiders
- Gregory M. Torre
- Erfahrung
